angiotensin ii, des-phe(8)- has been researched along with Adenocarcinoma, Basal Cell in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ager, EI; Chan, J; Chong, WW; Christophi, C; Neo, JH; Wen, SW | 1 |
| Bellini, G; Bernardi, S; Buri, L; Burrell, LM; De Manzini, N; Fabris, B; Giacomel, G; Palmisano, S; Sabato, N; Toffoli, B; Velkoska, E; Zanconati, F; Zennaro, C | 1 |
| Fan, L; Feng, Y; Gao, B; Li, Q; Ma, Q; Ni, L; Qian, Y; Wan, H; Xiang, Y | 1 |
| Gallagher, PE; Krishnan, B; Tallant, EA; Torti, FM | 1 |
| Dubey, P; Gallagher, PE; Krishnan, B; Smith, TL; Tallant, EA; Torti, FM; Willingham, MC; Zapadka, ME | 1 |
| Callahan, MF; Cline, JM; Ferrario, CM; Gallagher, PE; Menon, J; Soto-Pantoja, DR; Tallant, EA | 1 |
6 other study(ies) available for angiotensin ii, des-phe(8)- and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.
Topics: Adenocarcinoma; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarkers, Tumor; Biphenyl Compounds; Captopril; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Irbesartan; Liver Neoplasms, Experimental; Mice; Mice, Inbred CBA; Molecular Targeted Therapy; Neoplasm Proteins; Neovascularization, Pathologic; Oligopeptides; Peptide Fragments; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Tetrazoles; Tumor Burden; Up-Regulation; Vascular Endothelial Growth Factor A | 2011 |
Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma.
Topics: Adenocarcinoma; Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Caco-2 Cells; Cell Cycle; Colonic Neoplasms; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Intestinal Mucosa; Male; Middle Aged; Peptide Fragments; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptor, Angiotensin, Type 1; Receptors, G-Protein-Coupled | 2012 |
Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Angiotensin I; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Lung Neoplasms; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinase Kinases; Neoplasm Invasiveness; Neovascularization, Pathologic; Peptide Fragments; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Renin-Angiotensin System; Signal Transduction; Survival | 2012 |
Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.
Topics: Adenocarcinoma; Angiotensin I; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Peptide Fragments; Placenta Growth Factor; Pregnancy Proteins; Prostatic Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2013 |
Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.
Topics: Adenocarcinoma; Aged; Angiotensin I; Animals; Antineoplastic Agents; Bone Marrow Cells; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Humans; Male; Mice; Mice, Nude; Mice, SCID; Middle Aged; Neoplasm Metastasis; Osteoclasts; Peptide Fragments; Prostatic Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2.
Topics: Adenocarcinoma; Angiotensin I; Animals; Cell Growth Processes; Cell Line, Tumor; Cyclooxygenase 2; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Peptide Fragments; RNA, Messenger; Xenograft Model Antitumor Assays | 2007 |